Glioma (Jan 2022)

Postoperative radiotherapy with concomitant temozolomide plus anlotinib for newly diagnosed glioblastoma: Study protocol for a multicenter, double-blind, randomized phase II trial

  • Yuanyuan Chen,
  • Baiqiang Dong,
  • Guihong Liu,
  • Pengfei Sun,
  • Meihua Li,
  • Xuejun Yang,
  • Shiyu Feng,
  • Liang Wang,
  • Yonghong Hua,
  • Ming Zhao,
  • Yanhui Liu,
  • Juntao Ran,
  • Li Qiao,
  • Xueguan Lu,
  • Hao Jiang,
  • Deqiang Mao,
  • Junxin Wu,
  • Xianming Li,
  • Wei Zheng,
  • Zhigang Liu,
  • Song Lin,
  • Meiling Deng,
  • Qunying Yang,
  • Chengcheng Guo,
  • Jing Li,
  • Zhong-ping Chen

DOI
https://doi.org/10.4103/glioma.glioma_17_22
Journal volume & issue
Vol. 5, no. 2
pp. 69 – 76

Abstract

Read online

Background and Aim: Postoperative radiotherapy with concomitant temozolomide (TMZ) followed by ≤ six cycles of adjuvant TMZ chemotherapy (Stupp regimen) is the standard treatment for newly diagnosed glioblastoma (GBM); however, its effectiveness is limited. Anlotinib inhibits both tumor angiogenesis and tumor cell proliferation by targeting multiple kinases, and showing promising results in preclinical GBM models. We designed a Phase II trial to assess the efficacy and safety of the Stupp regimen plus anlotinib. Methods/Design: This is a multicenter, double-blind, randomized, placebo-controlled trial with an expected 150 patients randomly assigned 1:1 ratio to receive TMZ-based radiochemotherapy with anlotinib (Stupp regimen + anlotinib) or placebo (Stupp regimen + placebo). Postoperative patient recruitment will begin in July 2021, the analysis of primary outcome measures will be completed in July 2023, and the study will finish in July 2024. Major eligibility criteria include histologically confirmed newly diagnosed GBM and an Eastern Cooperative Oncology Group performance score ≤2. Other criteria for inclusion include age ≥18 years and lack of significant comorbidity. In this study, the primary endpoint will be the median progression-free survival (PFS). Secondary endpoints include 1-year overall survival rate, PFS at 6 months, overall response rate, duration of response, disease control rate, quality of life, and toxicity. The protocol has received approval from Sun Yat-sen University Cancer Center Ethics Committee (Approval No. B2021-073-01; approved on April 19, 2021). Discussion: Updated treatment modalities are required for newly diagnosed GBM. Our proposed treatment modality of the Stupp regimen combined with anlotinib therapy are waiting conclusion. Trial Registration: This study was registered with ClinicalTrials.gov under identifier NCT04959500 on July 13, 2021.

Keywords